Compare Elder Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PROCTER & GAMBLE HEALTH ELDER PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x -0.2 52.7 - View Chart
P/BV x 0.1 4.8 2.1% View Chart
Dividend Yield % 0.0 10.0 -  

Financials

 ELDER PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PROCTER & GAMBLE HEALTH
Dec-18
ELDER PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3803,549 10.7%   
Low Rs1881,301 14.4%   
Sales per share (Unadj.) Rs491.2511.4 96.0%  
Earnings per share (Unadj.) Rs-3.261.3 -5.2%  
Cash flow per share (Unadj.) Rs14.474.0 19.5%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs376.5927.8 40.6%  
Shares outstanding (eoy) m20.5416.60 123.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.7 12.2%   
Avg P/E ratio x-89.339.6 -225.6%  
P/CF ratio (eoy) x19.732.8 60.2%  
Price / Book Value ratio x0.82.6 28.9%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m5,83340,257 14.5%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m2,1791,313 166.0%   
Avg. sales/employee Rs ThNM7,486.7-  
Avg. wages/employee Rs ThNM1,157.6-  
Avg. net profit/employee Rs ThNM897.2-  
INCOME DATA
Net Sales Rs m10,0898,490 118.8%  
Other income Rs m257244 105.2%   
Total revenues Rs m10,3468,734 118.5%   
Gross profit Rs m-7921,482 -53.4%  
Depreciation Rs m361211 171.1%   
Interest Rs m2,7560-   
Profit before tax Rs m-3,6531,514 -241.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,71366 5,659.6%   
Tax Rs m125563 22.2%   
Profit after tax Rs m-651,017 -6.4%  
Gross profit margin %-7.817.5 -45.0%  
Effective tax rate %-3.437.1 -9.2%   
Net profit margin %-0.612.0 -5.4%  
BALANCE SHEET DATA
Current assets Rs m9,24015,343 60.2%   
Current liabilities Rs m9,9981,960 510.0%   
Net working cap to sales %-7.5157.6 -4.8%  
Current ratio x0.97.8 11.8%  
Inventory Days Days4649 95.0%  
Debtors Days Days6028 210.7%  
Net fixed assets Rs m10,1241,209 837.2%   
Share capital Rs m206166 123.9%   
"Free" reserves Rs m5,58215,235 36.6%   
Net worth Rs m7,73415,401 50.2%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88217,595 130.1%  
Interest coverage x-0.3NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 91.4%   
Return on assets %11.85.8 203.4%  
Return on equity %-0.86.6 -12.8%  
Return on capital %22.310.3 217.5%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3071,636 18.7%   
Fx outflow Rs m1254,368 2.9%   
Net fx Rs m181-2,732 -6.6%   
CASH FLOW
From Operations Rs m11,754-1,304 -901.5%  
From Investments Rs m-56112,697 -4.4%  
From Financial Activity Rs m-6,762-301 2,250.2%  
Net Cashflow Rs m4,43211,093 40.0%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.5 18.2 41.2%  
FIIs % 16.8 1.0 1,680.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 29.1 124.1%  
Shareholders   16,479 28,591 57.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS